One-month delay in MTX initiation on RA outcomes: 1-year ancillary analysis of the VACIMRA trial.
The VACIMRA trial demonstrated that delaying MTX initiation in RA by 1 month after the 13-valent pneumococcal conjugate vaccine (PCV13) improves humoral responses at 1 and 12 months. Whether this delay impacts disease activity and radiographic progression over 1&#x…